First of all, Kangmei Pharmaceutical's alleged fraud has dealt a serious blow to the company's reputation. According to media reports, the management of Kangmei Pharmaceutical has known that the independent audit is abnormal, but it still continues to publish false financial data. These actions not only violate the relevant laws and regulations, but also seriously hurt the interests of investors and market confidence. Therefore, investors have doubts about the company's financial data, leading to a decline in the stock price.
Secondly, the company's performance also affects the stock price. In the first half of 20 19, Kangmei Pharmaceutical's net profit decreased by nearly 90% year-on-year. In 20 18, the company's net profit was also negative. In addition, the company still has problems such as large debt scale and high non-performing debt ratio, which also directly affects the company's operation and market performance. Therefore, investors are worried about the future development of the company.
Finally, the trend of the whole pharmaceutical industry may also have an impact on Kangmei Pharmaceutical's share price. At present, the downward pressure on the global economy is increasing, and the competition and pressure faced by the pharmaceutical market are also increasing. In addition, policy adjustment and strengthening supervision have also brought many challenges to the pharmaceutical industry. Therefore, the unfavorable factors of the whole industry have also affected the share price performance of Kangmei Pharmaceutical.
To sum up, Kangmei Pharmaceutical's daily limit is mainly affected by the company's financial data fraud, declining performance and unfavorable factors in the industry. Investors need to be cautious, strengthen risk awareness and be more cautious when choosing investment targets.